Using a S1PR1-selective agonist, SEW2871 [39], we further tested the potential that interventions selectively targeting S1PR1 signalling pathways could ameliorate the pathological progression of SVD through protection of BBB integrity. This evidence concerns the gene S1PR1 and snowflake vitreoretinal degeneration.